- Home
- GMAB vs ERIE Comparison
GMAB vs ERIE Comparison
Compare GMAB & ERIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ERIE
- Stock Information
- Founded
- GMAB 1999
- ERIE 1925
- Country
- GMAB Denmark
- ERIE United States
- Employees
- GMAB N/A
- ERIE N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ERIE Specialty Insurers
- Sector
- GMAB Health Care
- ERIE Finance
- Exchange
- GMAB Nasdaq
- ERIE Nasdaq
- Market Cap
- GMAB 17.4B
- ERIE 19.2B
- IPO Year
- GMAB N/A
- ERIE 1995
- Fundamental
- Price
- GMAB $28.66
- ERIE $284.84
- Analyst Decision
- GMAB Strong Buy
- ERIE
- Analyst Count
- GMAB 7
- ERIE 0
- Target Price
- GMAB $41.50
- ERIE N/A
- AVG Volume (30 Days)
- GMAB 2.6M
- ERIE 150.8K
- Earning Date
- GMAB 11-06-2025
- ERIE 10-30-2025
- Dividend Yield
- GMAB N/A
- ERIE 1.92%
- EPS Growth
- GMAB 77.72
- ERIE 15.90
- EPS
- GMAB 21.62
- ERIE 12.39
- Revenue
- GMAB $3,646,881,232.00
- ERIE $4,040,325,000.00
- Revenue This Year
- GMAB $24.92
- ERIE $10.96
- Revenue Next Year
- GMAB $15.97
- ERIE $8.12
- P/E Ratio
- GMAB $1.33
- ERIE $22.99
- Revenue Growth
- GMAB 32.97
- ERIE 9.53
- 52 Week Low
- GMAB $17.24
- ERIE $279.78
- 52 Week High
- GMAB $33.65
- ERIE $456.93
- Technical
- Relative Strength Index (RSI)
- GMAB 40.06
- ERIE 33.37
- Support Level
- GMAB $28.08
- ERIE $281.89
- Resistance Level
- GMAB $29.35
- ERIE $290.88
- Average True Range (ATR)
- GMAB 0.65
- ERIE 10.27
- MACD
- GMAB -0.27
- ERIE -3.26
- Stochastic Oscillator
- GMAB 25.93
- ERIE 8.57
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.